Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Apidra Generic Name & Formulations
Legal Class
Rx
General Description
Insulin glulisine (rDNA origin) 100 Units/mL; soln for SC inj or continuous subcutaneous insulin infusion pump, or IV inj; contains m-cresol.
How Supplied
Vial (10mL)—1; Apidra SoloStar prefilled pen (3mL)—5
Manufacturer
Generic Availability
NO
Apidra Indications
Indications
Diabetes.
Apidra Dosage and Administration
Adults and Children
<4yrs: not established. ≥4yrs: Individualize. Rotate inj sites (abdomen, thigh, upper arm). For SC inj: give 15mins before meal or within 20mins after starting meal; use with an intermediate or long-acting insulin. For continuous SC infusion pump: do not dilute or mix insulins in pump; change Apidra in the reservoir and infusion sets at least every 48 hours. For IV inj: dilute Apidra; give only under medical supervision; closely monitor blood glucose and potassium.
Apidra Contraindications
Contraindications
During episodes of hypoglycemia.
Apidra Boxed Warnings
Not Applicable
Apidra Warnings/Precautions
Warnings/Precautions
Instruct patients on proper administration of insulin, type of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Visual impairment. Renal or hepatic impairment: monitor more frequently and adjust dose if needed. Elderly. Pregnancy. Nursing mothers.
Apidra Pharmacokinetics
See Literature
Apidra Interactions
Interactions
Do not mix with insulins other than NPH; draw insulin glulisine into syringe first, inject immediately after mixing. Caution with K+-depleting drugs or those sensitive to serum potassium concentrations; may cause hypokalemia. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by antidiabetic agents, ACEIs, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia.
Apidra Adverse Reactions
Adverse Reactions
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, weight gain; hypokalemia.
Apidra Clinical Trials
See Literature
Apidra Note
Not Applicable
Apidra Patient Counseling
See Literature
